JoVE Logo

Anmelden

7.11 : Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.

A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote glycine release, increasing chloride influx into postsynaptic neurons and reducing excitability.

GABA mimetics, such as baclofen, activate GABAB receptors, leading to hyperpolarization of neuronal membranes and reduced excitability. Baclofen suppresses the release of excitatory transmitters in the brain and spinal cord, suppressing sensory afferents, interneurons, and motor neurons.

Benzodiazepines like diazepam bind to the allosteric site of GABAA receptors and facilitate GABA's action in the CNS. Diazepam reduces spasticity, particularly in the spinal cord, but sedation can occur at doses required to reduce muscle tone.

Tags

Spasmolytic AgentsMuscle SpasmsSpasticityChemical ClassificationCentrally Acting Spasmolytics2 agonistTizanidine2 adrenoceptorsGlutamateGlycineChloride InfluxGABA MimeticsBaclofenGABAB ReceptorsHyperpolarizationBenzodiazepinesDiazepamGABAA ReceptorsCNS Sedation

Aus Kapitel 7:

article

Now Playing

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

840 Ansichten

article

7.1 : Neuromuskuläre Verbindung und Blockade

Skeletal Muscle Relaxants

2.7K Ansichten

article

7.2 : Klassifizierung von Skelettmuskelrelaxantien

Skeletal Muscle Relaxants

2.3K Ansichten

article

7.3 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.3K Ansichten

article

7.4 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Pharmakologische Wirkungen

Skeletal Muscle Relaxants

368 Ansichten

article

7.5 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Pharmakokinetik

Skeletal Muscle Relaxants

421 Ansichten

article

7.6 : Depolarisierende Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.1K Ansichten

article

7.7 : Depolarisierende Blocker: Pharmakokinetik

Skeletal Muscle Relaxants

296 Ansichten

article

7.8 : Direkt wirkende Muskelrelaxanzien: Dantrolen und Botulinumtoxin

Skeletal Muscle Relaxants

629 Ansichten

article

7.9 : Skelettmuskelrelaxanzien: Nebenwirkungen

Skeletal Muscle Relaxants

316 Ansichten

article

7.10 : Skelettmuskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

443 Ansichten

article

7.12 : Peripher und zentral wirkende Muskelrelaxanzien: Ein Vergleich

Skeletal Muscle Relaxants

3.1K Ansichten

article

7.13 : Zentral wirkende Muskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

595 Ansichten

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten